Abstract
This study was designed to examine the type of changes experienced by the CB1 receptor, a key element of the cannabinoid signaling system, in the basal ganglia of different mouse mutants generated by deletion of specific genes associated with the development of Parkinson’s disease in humans [PARK1 (α-synuclein), PARK2 (parkin) or PARK6 (PINK1)]. We observed that CB1 receptor-mRNA levels were significantly reduced in the caudate-putamen in the three models under examination when animals were analyzed at early phases (≤ 12 months of age). This decrease was, in general, associated with a reduction in CB1 receptor binding in the substantia nigra and the globus pallidus, particularly in the case of α-synuclein-deficient mice. By contrast, both parameters, mRNA levels and binding for the CB1 receptor, showed an elevation in the same areas when animals were analyzed at older ages, mainly in the case of the CB1 receptor binding in the substantia nigra. In summary, our data revealed the existence of a biphasic response for CB1 receptors, with losses at early phases, when dopaminergic dysfunction is possibly the major event that takes place, followed by upregulatory responses at advanced phases characterized by the occurrence of evident nigrostriatal pathology including neuronal death in some cases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berrendero F, Romero J, García-Gil L, Suárez I, De la Cruz P, Ramos JA, Fernández-Ruiz J (1998) Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochim Biophys Acta 1407:205–214
Brotchie JM (2003) CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 3:54–61
Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22:8797–8807
Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432–1438
Fernández-Espejo E, Caraballo I, Rodríguez de Fonseca F, El Banoua F, Ferrer B, Flores JA, Galán-Rodríguez B (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18:591–601
García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134:162–170
García-Arencibia M, Ferraro L, Tanganelli S, Fernández-Ruiz J (2008) Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett 438:10–13
Gerdeman GL, Fernández-Ruiz J (2008) The endocannabinoid system in the physiology and pathophysiology of the basal ganglia. In: Kofalvi A (ed) Cannabinoids and the brain. Springer, Berlin, pp 423–483
González S, Mena MA, Lastres-Becker I, Serrano A, de Yébenes JG, Ramos JA, Fernández-Ruiz J (2005) Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Res 1046:195–206
González S, Scorticati C, García-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J (2006) Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 1073–1074:209–219
Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agrò A, Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22: 6900–6907
Herkenham M, Lynn AB, Little MD, Melvin LS, Johnson MR, de Costa DR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563–583
Itier JM, Ibañez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, García de Yébenes J (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 12:2277–2291
Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B-Y, Jenner P, Ramos JA, Fernández-Ruiz J (2001) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14:1827–1832
Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19:96–107
Lehmann A, Gautier M (1974) Stereotaxic atlas of the brain of the mouse. Centre National de la Recherche Scientifique, Paris Book/1–68
Mailleux P, Vanderhaeghen JJ (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61:1705–1712
Pazos MR, Sagredo O, Fernández-Ruiz J (2008) The endocannabinoid system in Huntington’s disease. Curr Pharm Des 23:2317–2325
Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, Bernardi G, Brusa L, Pierantozzi M, Stanzione P, Maccarrone M (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57: 777–779
Rodríguez-Navarro JA, Casarejos MJ, Menéndez J, Solano RM, Rodal I, Gómez A, Yébenes JG, Mena MA (2007) Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J Neurochem 103:98–114
Romero J, Berrendero F, Garcia-Gil L, de la Cruz P, Ramos JA, Fernández-Ruiz J (1998) Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience 84:1075–1083
Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernández-Ruiz J, de Yébenes JG, Ramos JA (2000) Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 66:485–494
Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro P (1994) Chronic CP-55, 940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. Neuroreport 5:2493–2496
Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J (2007) Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol 36:82–91
Sañudo-Peña MC, Tsou K, Walker JM (1999) Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65: 703–713
Zhao P, Ignacio S, Beattie EC, Abood ME (2008) Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci 27:572–579
Acknowledgments
This work was supported by grants from MEC (SAF2006-11333), CIBERNED (CB06/05/0089) and CAM (S-SAL-0261/2006) to MGA, CG and JFR, CIBERNED (CB06/05/0059) to JARN, MAM and JGY, and BMBF (NGFN2, 01GS0472) and DFG (GI342/3-1) to AK, SG and GA. The authors are indebted to Patricia Rodríguez Valsero and Yolanda García Movellán for technical and administrative support.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag/Wien Printed in Germany
About this chapter
Cite this chapter
García-Arencibia, M. et al. (2009). Cannabinoid CB1 Receptors are Early DownRegulated Followed by a Further UpRegulation in the Basal Ganglia of Mice with Deletion of Specific Park Genes. In: Giovanni, G., Di Matteo, V., Esposito, E. (eds) Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra. Journal of Neural Transmission. Supplementa, vol 73. Springer, Vienna. https://doi.org/10.1007/978-3-211-92660-4_22
Download citation
DOI: https://doi.org/10.1007/978-3-211-92660-4_22
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-92659-8
Online ISBN: 978-3-211-92660-4
eBook Packages: MedicineMedicine (R0)